Plan to combat extensively drug-resistant tuberculosis; recommendations of the Federal Tuberculosis Task Force
Plan to combat extensively drug-resistant tuberculosis; recommendations of the Federal Tuberculosis Task Force
复制标题
DOI：
--
复制
发表时间：
2009-02
期刊：
影响因子：
--
通讯作者：
K. Castro;P. Lobue;C. Sizemore
中科院分区：
文献类型：
--
作者：
K. Castro;P. Lobue;C. Sizemore
在1985- 1992年期间，美国面临着前所未有的结核病死灰复燃。这种复苏伴随着耐多药结核病（MDR TB）的增加，MDR TB被定义为对两种最有效的一线治疗药物异烟肼和利福平耐药的结核病。此外，几乎无法治愈的M.结核病正在全球范围内出现。广泛耐药（XDR）结核病定义为耐多药结核病，也耐最有效的二线治疗药物，通常用于治疗耐多药结核病：氟喹诺酮类和至少一种用于治疗结核病的三种注射二线药物（阿米卡星，卡那霉素或卷曲霉素）。广泛耐药结核病已在世界所有地区得到确认，包括美国。
During 1985--1992, the United States was confronted with an unprecedented TB resurgence. This resurgence was accompanied by a rise in multidrug-resistant TB (MDR TB), which is defined as TB that is resistant to the two most effective first-line therapeutic drugs, isoniazid and rifampin. In addition, virtually untreatable strains of M. tuberculosis are emerging globally. Extensively drug-resistant (XDR) TB is defined as MDR TB that also is resistant to the most effective second-line therapeutic drugs used commonly to treat MDR TB: fluoroquinolones and at least one of three injectable second-line drugs used to treat TB (amikacin, kanamycin, or capreomycin). XDR TB has been identified in all regions of the world, including the United States.